BlackRock, Inc. 13D and 13G filings for Allogene Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale |
2025-03-31 | 13G | Allogene Therapeutics, Inc. ALLO |
BlackRock Inc. BLK |
11,450,079 5.300% |
-6,322,666 (-35.58%) |
Filing |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Allogene Therapeutics, Inc. ALLO |
BlackRock Inc. BLK |
17,772,745 8.500% |
0 (Unchanged) |
Filing |
| 2024-10-22 3:24 pm Purchase |
2024-09-30 | 13G | Allogene Therapeutics, Inc. ALLO |
BlackRock Inc. BLK |
17,772,745 8.500% |
7,770,941 (+77.70%) |
Filing |
| 2024-01-29 5:25 pm Purchase |
2023-12-31 | 13G | Allogene Therapeutics, Inc. ALLO |
BlackRock Inc. BLK |
10,001,804 5.900% |
1,115,232 (+12.55%) |
Filing |
| 2023-02-03 12:09 pm Purchase |
2022-12-31 | 13G | Allogene Therapeutics, Inc. ALLO |
BlackRock Inc. BLK |
8,886,572 6.200% |
8,886,572 (New Position) |
Filing |